microRNAs in the control of lymphocytes response by Rossi, Annalisa
microRNAs in the control of lymphocytes response 
 
 
  
 
 
1 
UNIVERSITA’ DEGLI STUDI DI NAPOLI 
FEDERICO II 
 
 
 
 
 
CORSO DI DOTTORATO IN GENETICA E 
MEDICINA MOLECOLARE 
XXII CICLO 
 
 
 
microRNAs in the control of lymphocytes response 
 
 
Dottoranda 
Dott.ssa Annalisa Rossi 
 
Tutor 
Ch.mo Prof. Massimo Mallardo 
 
Coordinatore 
Ch.mo Prof. Roberto di Lauro 
 
 
 
 
ANNO ACCADEMICO 2009/2010 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
2 
INDEX 
 
 
CHAPTER 1 : Introduction 
 
5 
1.1 Biogenesis of microRNAs 
 
pag.6 
1.2 Mechanisms of microRNA action 
 
pag.10 
1.3 Regulation of miRNA biogenesis 
 
pag.12 
1.4 miRNA functions 
 
pag.18 
1.5 miRNA in Immune System  
 
pag.20 
1.5.1 miRNA during the Innate Immune            
Response  
 
pag.21 
1.5.2 miRNAs in the Adaptive Immune 
Responses 
 
pag.24 
1.5.3 miRNA-155: a regulator of B - and T-cell 
maturation and the innate immune response 
 
pag.30 
1.6 Aim 
 
pag.34 
CHAPTER 2: Materials and Methods 
 
37 
2.1 Cell culture 
 
pag.37 
2.2 RNA preparation and northern blot 
 
pag.37 
2.3 Western blot analysis 
 
pag.39 
2.4 Cloning and mutagenesis of BIC/miR-155 
promoter 
 
pag.40 
2.5 Reporter analysis 
 
pag.41 
2.6 Chromatin immunoprecipitation assay 
 
pag.42 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
3 
2.7 Preparation of nuclear extracts and 
electrophoresis mobility shift assay 
 
pag.43 
2.8 Transient transfection pag.44 
2.9 Viral generation, infection and time course 
 
pag.44 
2.10 Transient transfection of MC3 
 
pag.45 
2.11 Prediction of potential miRNAs 
 
pag.46 
2.12 DNA plasmids 
 
pag.46 
2.13 Dicer RNase assay 
 
pag.47 
2.14 Comparative analysis of nucleotide 
sequence 
 
pag.47 
CHAPTER 3: Epstein-Barr virus latent 
membrane protein 1 trans-activates miR-
155 transcription through the NF-!B 
pathway 
 
49 
3.1 The expression of miR-155 is regulated by 
LMP1 
 
pag.49 
3.2 miR-155 expression can be driven through 
activation of two NF-!B elements in the 
BIC/miR-155 promoter 
 
pag.51 
3.3 The NF-!B elements in the BIC/miR-155 
promoter bind NF-!B factors in vitro and in 
vivo in MC3 cells 
 
pag.53 
3.4 LMP1 requires intact NF-!B cis-elements 
to enhance miR-155 expression  
 
pag.57 
 
3.5 The binding of p65/RelA to both NF-!B 
cis-elements of miR-155 promoter is 
temporally correlated to LMP1 expression 
 
 
 
pag.60 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
4 
3.6 The protein levels of transcription factor 
PU.1 correlates with LMP1-induced miR-155 
expression 
 
pag.63 
3.7 Discussion 
 
pag.64 
CHAPTER 4: Computational analysis and 
in vivo validation of a microRNA encoded 
by the IBTK gene, a regulator of B-
lymphocytes differentiation and survival 
 
68 
4.1 IBTK gene encoded a new microRNA 
 
pag.68 
4.2 Discussion 
 
pag.73 
Bibliography 
 
pag.75 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
5 
Chapter 1: Introduction 
 
The discovery of very short non-coding RNAs as regulators of gene 
activity began almost 15 years ago when Victor Ambros and colleagues 
studying larval development in the nematode worm C. elegans 
discovered a gene, lin-4, that encoded short RNA transcripts able to 
inhibit translation of the messenger RNA of a different gene, lin-14, by 
binding to its 3’ untranslated region (UTR) (figure 1) [1]. In hindsight, 
lin-4 was the first of the microRNA (miR o miRNA) class of genes to 
be characterized.  Since this initial observation, more than 700 miRNAs 
(miRNA registry at http://www.mirbase.org/) have been identified in 
mammalian cells and they have been shown to be involved in a wide of 
physiological responses, including development, differentiation and 
homeostasis [2,3].  
               
Figure 1 - The molecular hallmarks of lin-4, the founding member of the 
microRNA family. (a) The precursor structure and mature miRNA sequence of lin-
4. (b) Sequence complementarity between lin-4 (red) and the 3!-untranslated region 
(UTR) of lin-14 mRNA (blue). lin-4 is partially complementary to 7 sites in the lin-
14 3! UTR; its binding to these sites of complementarity brings about repression of 
LIN-14 protein synthesis. From Lin He et al. (2004). MicroRNAs: small RNAs 
with a big role in gene regulation. Nature Reviews Genetics, 5:522-531. 
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1.1 Biogenesis of microRNAs 
miRNAs are short single-stranded RNA molecules of 19–23 
nucleotides in length. Approximately half of all human miRNA genes 
are contained within the introns of protein-coding or non-protein 
coding genes, while others reside apart from known genes, or in the 
exons of untranslated genes[4].   The transcription of most miRNA genes 
is mediated by RNA polymerase II (Pol II), although a minor group of 
miRNAs that are associated with Alu repeats can be transcribed by Pol 
III (for miRNA biogenesis scheme see figure 2)[5-7]. A range of Pol II-
associated transcription factors control miRNA gene transcription[8]. 
Thus, Pol II-dependent transcription allows miRNA genes to be 
elaborately regulated in specific conditions and cell types. Furthermore, 
some miRNA primary transcripts encode only a single mature miRNA, 
while other loci contain clusters of microRNAs that appear to be 
produced from a single primary transcript[4]. The primary transcript, pri-
miRNA, is an imperfect hairpin characterized by a stem-loop structure 
and two single strand RNA (ssRNA) basal segments. A nuclear protein 
complex called the “Microprocessor”, consisting of the Drosha type III 
RNase, the double-stranded RNA-binding protein DGCR8 (DiGeorge 
syndrome critical region gene 8, or Pasha), and others proteins, interact 
with pri-miRNAs through the single strand RNA basal segments and 
the stem of ~33 bp, and assists Drosha to cleave the substrate ~11 base 
pair away from the ssRNA-dsRNA junction[9]. Drosha liberates an 60-
to-80-nucleotide long hairpin-shaped precursor, pre-miRNA, with 2-nt 
3! overhang, which is recognized and exported to the cytoplasm by 
exportin-5 via a Ran-GTP-dependent mechanism[10]. 
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Figure 2 - The miRNA processing. In the nucleus, RNA polymerase II or III 
generates the primary miRNA transcript (pri-miRNA) that is then cleaved by the 
microprocessor complex Drosha–DGCR8 (Pasha). The resulting precursor hairpin, 
the pre-miRNA, is exported from the nucleus by Exportin-5–Ran-GTP. In the 
cytoplasm, Dicer in complex with the double-stranded RNA-binding protein TRBP 
cleaves the pre-miRNA hairpin to its mature length. The functional strand of the 
mature miRNA is loaded into the RNA-induced silencing complex (RISC), where it 
guides RISC to silence target mRNAs. From Winter J. et al. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nature Reviews 
Molecular Cell Biology, 11: 228 – 234. 
 
 
Recent studies show that pri-miRNA processing might be a co-
transcriptional process[11-13]. The initial model was based on the finding 
that Drosha processing of intronic miRNA precedes the splicing of a 
host intron (figure 3a)[11]. Interestingly, the cleavage of the intron by 
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Drosha does not impair splicing[11]. This is consistent with a previous 
‘exon-tethering’ model[14], which suggested that the exons of Pol II 
transcripts are cotranscriptionally assembled into the spliceosome. 
Thus, Drosha processing might take place after the transcript is tied to 
the splicing commitment complex (the early spliceosome complex), but 
before the intron is excised. Thus, cropping and splicing might be 
highly coordinated co-transcriptional processes. Supporting this, pri-
miRNA and Drosha localize to the transcription sites and pri-miRNAs 
are enriched in the chromatin-associated nuclear fraction[12-13]. Apart 
from canonical intronic miRNAs, small groups of miRNA-like RNAs 
have been discovered in introns in flies and mammals[15-17]. These small 
RNAs are embedded in short introns, and their biogenesis does not 
require Drosha processing (figure 3b)[18]. Following the complex of 
splicing, the branch point of the lariat-shaped intron is resolved and the 
disbranched intron forms a hairpin structure that resembles pre-
miRNA. Some precursors (mirtrons) contain extended tails at either the 
5! or 3! end, which therefore require exonucleolytic trimming in order 
to become a substrate for nuclear export (figure 3b). Therefore, it is 
becoming clear that multiple non-canonical pathways can feed pre-
miRNAs into the miRNA pathway through Drosha-independent 
processes.  
microRNAs in the control of lymphocytes response 
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Figure 3 – Intronic miRNAs biogenesis pathway. (a) Canonical intronic miRNAs 
are processed co-transcriptionally before splicing. The miRNA-containing introns 
are spliced more slowly than the adjacent introns for unknown reasons. The 
splicing commitment complex is thought to tether the intron while Drosha cleaves 
the miRNA hairpin. The pre-miRNA enters the miRNA pathway, whereas the rest 
of the transcript undergoes pre-mRNA splicing and produces mature mRNA for 
protein synthesis. (b) Non-canonical intronic small RNAs are produced from 
spliced introns and debranching. Because such small RNAs (called mirtrons) can 
derive from small introns that resemble pre-miRNAs, they bypass the Drosha-
processing step. Some introns have tails at either the 5! end or 3! end, so they need 
to be trimmed before pre-miRNA export. m7G, 7-methylguanosine. Modified from 
V. Narry Kim et al. (2009). Biogenesis of small RNAs in animals. Nature Reviews 
Molecular Cell Biology 10:126-139. 
 
 
In the cytoplasm, the pre-miRNAs are further processed by a protein 
complex containing the Dicer type III RNase that cleaves the miRNA 
to its mature size[19-24]. In general, only one strand of the original 
precursor is kept as a mature microRNA. The mature miRNA becomes 
associated with a final protein complex called the miRISC (microRNA-
induced silencing complex), which typically contains an Argonaute 
family protein, and which carries out the silencing of the genes targeted 
by the miRNA (figure 2). MiRNAs are believed to either block mRNA 
translation or reduce mRNA stability after imperfect binding of the 
a b 
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guide strand to miRNA-recognition elements (MREs) within target 
mRNA 3’ UTR. Originally, it was believed that the specificity of this 
response was mediated by the “seed” region, which is localized at 
residues 2–8 at the 5’ end of the miRNA guide strand. However, it now 
seems that this was an over-simplification and that miRNA targeting is 
influenced by additional factors such as the presence and cooperation 
between multiple MREs, the spacing between MREs, proximity to the 
stop codon, position within the 3’ UTR, AU composition, and target 
mRNA secondary structure[25-28]. 
                      
1.2 Mechanisms of microRNA action  
The mechanism of miRNA-mediated gene regulation, and how it 
affects active translation (figure 4a), is a matter of controversy. The 
available data support two possible views: first, the translation of 
mRNAs is inhibited at the level of initiation, and the silenced mRNAs 
are occupied by few or no ribosomes[29]; second, the inhibition takes 
place at a step that is subsequent to initiation, and the silenced mRNAs 
sediment in the polyribosome fractions in a sucrose gradient. The first 
view is supported from several evidences: 
i. AGO2, an Argonaute protein, binds the m7G (7-
methylguanosine) cap of mRNAs through a domain that shares 
structural features with the translation initiation factor eIF4E, 
suggesting that when AGO2 is recruited to the 3! UTR of a target 
mRNA by miRNAs, it hinders the m7G cap recognition by the 
translation apparatus[30] (figure 4b).  
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ii. miRNA translational inhibition is reversed, in an in vitro system, 
by increased levels of the eIF4F complex which includes the 
m7G cap-binding eIF4E translation factor[31].  
iii. miR-2, in vitro, inhibits the assembly of the 48S complex, the 
translational complex that precedes the addition of the large 
ribosomal subunit to form the competent ribosome[32]. 
iv. eIF6, the ribosome inhibitory protein was co-purified with 
RISC[33].  
Nonetheless, cellular subfractionation studies indicate that many 
miRNAs are found in the polyribosome fraction, which would be most 
consistent with a post-initiation inhibition by miRNAs; this could result 
from rapid degradation of the protein product encoded by the targeted 
mRNA, or from a high rate of ribosome drop-off during elongation, 
resulting in incomplete protein products that would be rapidly degraded 
(figure 4c)[34,35].  
However, others observed variable levels of target mRNA degradation, 
and colocalization of the RISC component with mRNA degradation 
factors in the P bodies (figure 4d)[36]. Sequestration of mRNAs in the P 
bodies and degradation could be a step that follows blocking of 
translation, or a causative event in miRNA repression. GW182, a P-
body component, has recently been shown to interact directly with 
AGO protein and to be recruited to the target mRNA in a let-7-
dependent manner[37,38]. 
The detailed mechanisms of miRNA activity, including a full list of the 
protein components of the active miRISC complex for various 
miRNAs, await further elucidation. A recent paper underscores this 
point with the surprising observation that under some conditions, such 
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as cell cycle arrest, microRNAs can upregulate translation of a target 
protein[39]. 
   
 
 
Figure 4 - Mechanism of miRNA-mediated gene regulation. (a) Active 
translation mechanism. (b) Translation of mRNAs is inhibited at the level of 
initiation. (c) The inhibition of mRNA target  takes place at a step subsequently to 
initiation. (d) Sequestration of mRNA target in the P bodies determines RNA 
degradation. From Stefani et  al. (2008). Small non-coding RNAs in animal 
development. Nature Reviews Molecular Cell Biology 9, 219-230. 
 
 
1.3 Regulation of miRNA biogenesis  
Expression profiling studies indicate that most miRNAs are under the 
control of developmental and/or tissue specific signalling[40]. Precise 
control of miRNA levels is crucial to maintain normal cellular 
functions, and dysregulation of miRNA is often associated with human 
diseases, such as cancer[41].  
Transcriptional control. Transcription is a major point of regulation in 
miRNA biogenesis. Numerous Pol II!associated transcription factors 
are involved in transcriptional control of miRNA genes. For instance, 
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MyoD1 (myogenin and myoblast determination), SRF (serum response 
factor), Mef2 (myocyte enhancer 2) bind upstream of miR-1 and miR-
133 loci and induce the transcription of these miRNAs during 
myogenesis[42,43]. Some miRNAs are under the control of 
tumour!suppressive or oncogenic transcription factors. The tumour 
suppressor p53 activates the miR-34 family[44], whereas the oncogenic 
protein  MyC transactivates or represses a number of miRNAs that are 
involved in the cell cycle and apoptosis[45,46]. Epigenetic control also 
contributes to miRNA gene regulation; the miR-203 locus frequently 
undergoes DNA methylation in T-cell lymphoma but not in normal T 
lymphocytes [47]. 
Post-transcriptional regulation. Drosha and Dicer processing confers 
another important point of regulation. As it is mentioned above, miR-1 
and miR-133 share common cis and trans  regulation mechanism, but 
the relative abundance of miR-1 or miR-133 differs dynamically in the 
heart and skeletal muscle at distinct  stage of development, which 
reflect a higher order of processing regulation[42,43].  miR!21 is induced 
in response to bone morphogenetic protein (BMP)/transforming growth 
factor!! (TGF !) signalling by regulating the Microprocessor activity, 
without transcriptional activation[48]. It was proposed that SMAD 
proteins activated by BMP/TGF! interact with Drosha and DDX5 (also 
known as p68) to stimulate Drosha processing. Although the detailed 
mechanism for this remains unclear, the Drosha mediated processing of 
miR-21 is strongly enhanced and the abundance of miR-21 increases 
(figure 5 b). Drosha-mediated cleavage can also be regulated for 
individual miRNAs: heterogeneous ribonucleoprotein particle A1 
(hnRNPA1) binds specifically pri-miR-18a and facilitates its 
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processing. Interestinly loss of (hnRNPA1) has impact only on miR-
18a, but not on other miRNAs that are located in the same miR-17 
genomic cluster (figure 5c) [48-50]. How many of such regulatory factors 
exist is unclear, but it is plausible that nuclear RNA binding proteins 
influence miRNA processing through specific interactions with a subset 
of pri!miRNAs.  
         
Figure 5 – miRNAs posttrascriptional regulation. (a) The microprocessor 
complex Drosha–DGCR8 cleaves the pri-miRNA, releasing the pre-miRNA. (b) 
TGF-beta signalling induces SMAD binding to the miR-21 precursor and enhances 
its efficient processing by Drosha. (c) Interaction of pri-miR-18a with hnRNP A1 
facilitates cleavage of this specific miRNA by Drosha. Modified from Winter J. et 
al. (2009). Many roads to maturity: microRNA biogenesis pathways and their 
regulation. Nature Reviews Molecular Cell Biology, 11: 228 – 234. 
 
 
The let!7 miRNAs show interesting expression regulation [51] The 
primary transcript of let!7 (pri!let!7) is expressed in both 
undifferentiated and differentiated ES (embryonic stem) cells, whereas 
mature let!7 is detected only in differentiated cells, indicating that 
let!7a might be post!transcriptionally controlled[52-54]. Similar 
post!transcriptional inhibition of let!7 also takes place in tumour 
cells[54]. Recent studies show that an RNA binding protein, LIN-28, is 
a 
b 
c 
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responsible for the suppression of let-7 biogenesis[55-58] (figure 6). 
Several different mechanisms of LIN-28 action have been proposed: 
blockage of Drosha processing [55,56], interference with Dicer processing 
[58,59] and terminal uridylation of pre!let!7[58]. Given the cytoplasmic 
localization of LIN-28 and its strong interaction with pre!let!7 (but not 
with pri!let!7)[58], LIN-28 is likely to function mainly in the cytoplasm 
by interfering with pre!let!7 processing and/or by inducing terminal 
uridylation of pre!let!7. The “u tail” (~14 nt) that is added to the 3! 
end of pre!let!7 blocks Dicer processing and facilitates the decay of 
pre!let!7 [59]. It is unknown how widespread this type of regulation is 
and which enzyme is responsible for pre!miRNA uridylation.  
 
 
Figure 6 - Different mechanisms suppress the maturation of let-7 by the RNA-
binding protein Lin-28. (a) Lin-28 inhibits Drosha-mediated processing of pri-let-
7. (b) Lin-28 inhibits Dicer-mediated cleavage of pre-let-7 and recruits a terminal 
uridylyl transferase (TUTase) to pre-let-7. The uridylated up-let-7 is not processed 
but is degraded by nucleases. From Winter J. et al. (2009). Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nature Reviews Molecular 
Cell Biology, 11: 228 – 234.  
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Turnover of miRNA is a largely unexplored area. RNA decay enzymes 
might target not only mature miRNAs but also the precursors (pri-
miRNAs and pre-miRNAs). Once bound to Ago proteins, mature 
miRNAs seem to be more stable than average mRNAs; the half!life of 
most miRNAs is greater than 14 hours [60]. However, certain miRNAs 
(for example, miR!29b) might be degraded much more rapidly than 
other miRNAs, which suggests a specific recognition of miRNA 
sequences by nucleases. The 3!" 5! exonuclease ERI1 (also known as 
THEX1) was previously shown to be responsible for the degradation of 
siRNAs in C. elegans [61]. A group of exoribonucleases named small 
RNA degrading nuclease (SDN) proteins were recently reported to 
affect the stability of miRNAs in plants[62]. However, it remains unclear 
which nucleases are responsible for miRNA degradation in animals. 
RNA editing is another possible way of regulating miRNA biogenesis. 
The alteration of adenines to inosines, a process that is mediated by 
adenine deaminases  (ADARs), has been observed in miR!142 [63]  and 
miR!151[64]. Because the modified pri!miRNAs or pre-miRNAs 
become poor substrates of RNase III proteins, editing of the precursor 
can interfere with miRNA processing. Editing can also change the 
target specificity of the miRNA if it occurs in miRNA sequences [65]. 
Feedback circuits in miRNA networks. miRNA biogenesis is 
controlled by multiple layers of feedback loops that involve the 
biogenesis factors, the miRNAs themselves and their targets [66].  Two 
types of feedback circuits are frequently observed: single!negative 
feedback and double!negative feedback. Single!negative feedback 
usually results in stable or oscillatory expression of both components, 
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whereas double!negative feedback serves as a bistable switch that 
results in mutually exclusive expression. Levels of Drosha and Dicer 
are controlled by single negative feedback to maintain the homeostasis 
of miRNA production [67,68]. Drosha constitutes a regulatory circuit 
together with DGCR8; Drosha downregulates DGCR8 by cleaving 
DGCR8 mRNA, whereas DGCR8 upregulates Drosha through protein 
stabilization (figure 8a,b). This loop seems to be highly effective 
because even when the DGCR8 gene copy number is reduced by 
one!half in Dgcr8 heterozygous cells, an almost normal level of 
DGCR8 protein is produced and miRNA levels are also unaffected. 
                           
Figure 7 – miRNAs feedback regulation. (a) DGCR8 enhances the protein 
stability of its partner Drosha. (b) Drosha cleaves two hairpin structures in the 
Dgcr8 mRNA, which is subsequently degraded. From Winter J. et al. (2009). Many 
roads to maturity: microRNA biogenesis pathways and their regulation. Nature 
Reviews Molecular Cell Biology, 11: 228 – 234.  
 
 
 
Human Dicer is controlled by its own product, let!7, which binds to the 
3! UTR and coding region of the Dicer mRNA [69,70]. This might explain 
why Dicer knockdown is often more transient and moderate than 
knockdown of other genes. Furthermore, numerous examples of 
single!negative feedback have been described in worms, flies and 
mammals, in which a transcription factor that transactivates miRNA is 
itself repressed by that same miRNA[66]. Double!negative feedback 
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control is also often used as an effective genetic switch of specific 
miRNAs during differentiation. One interesting example is the 
conserved loop that involves the miR!200 family and the 
transcriptional repressors ZEB1 and ZEB2 that functions in epithelial–
mesenchymal transition [71].  miR-200 family suppresses the ZEB1 and 
ZEB2 protein synthesis, whereas blocks miRs maturation.  
 
1.4 miRNA functions 
Targeted deletion of Dicer, the essential miRNA-processing enzyme, in 
mice causes embryonic lethality before embryonic day (E) 7.5, 
suggesting an essential role for miRNAs in development[72].  
Neurogenesis. miRNAs regulate key events during neurogenesis in 
multiple species. For example, in C. elegans, two bilaterally symmetric 
gustatory neurons, ASE left (ASEL) and ASE right (ASER) exhibit left 
and right asymmetric molecular features. Auto-regulatory feedback 
loops involving distinct miRNAs control the cell-fate decision between 
the two asymmetric states. The transcription factors die-1 or cog-1 
specify ASEL or ASER fates, respectively, by activating genes that 
distinguish ASEL from ASER, including the miRNAs lsy-6 and miR-
273, which repress the ASER or ASEL fate, respectively. These 
cascades reinforce transcriptional programs leading to left–right 
asymmetry[73].  
Fragile X syndrome is one of the commonly inherited mental 
retardation syndromes. The gene responsible for fragile X syndrome, 
FMR1 (fragile X retardation 1), is located on human chromosome 10. 
This syndrome is caused by loss of an RNA-binding protein called 
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familial mental retardation protein, which has been reported to be 
regulated by miRNAs [74].  
Tourette’s syndrome is another neuropsychiatric disorder among 
humans in which the role of miRNA has been reported [75]. The 3’-UTR 
of the SLITRK1 gene contains the binding site of miR-189, which is 
mutated in some Tourette’s syndrome patients [75]. In situ hybridization 
of SLITRK1 mRNA and miR-189 revealed coexpression in the 
neuroanatomical circuits most commonly implicated in Tourette’s 
syndrome. This demonstrates how an miRNA can be involved in the 
establishment of a disease phenotype [76].  
Irrespective of diseases, miRNAs are also involved in many other 
physiological functions. The expression of miR-375 takes place in 
murine pancreatic islets cells and plays an important role in regulation 
of the myotrophin gene and thereby glucose-stimulated insulin 
exocytosis [77]. Higher expression levels of miR-375 have been reported 
in pituitary glands of zebra fish embryoswhich indicates its possible 
involvement in neuroendocrine activities [78,79].   
Pregnancy. Recently, Chim et al. have reported the existence of 
placental miRNA in maternal plasma, which opens up new possibilities 
of using the miRNAs as molecular markers for pregnancy monitoring. 
Four placental miRNAs (miR-141, miR-149, miR-299-5p and miR-
135b) were found to be present at higher levels in maternal plasma 
during the predelivery period than after delivery. The measurement of 
miRNA in maternal plasma for prenatal monitoring and diagnosis 
would be an interesting future research direction [80].   
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1.5 miRNA in Immune System 
Regulation of the immune system is vital to preventing many 
pathogenic disorders including autoimmune disease and cancers. 
Mammals have developed a complex system of checks and balances for 
immune regulation in order to maintain self tolerance while allowing 
immune responses to foreign pathogens, most of which are not fully 
understood. Recently, it has become evident that miRNAs play an 
important role in regulating immune response, as well as immune cell 
development. Amazingly, a relatively small number of specific 
miRNAs are coming to light as important regulators of the immune 
system (figure 8) [81-84].  
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1.5.1 miRNA during the Innate Immune Response  
miRNAs have an important role in modulating innate immune 
responses, the first line of defense to bacterial, viral, and other 
pathogens. During inflammatory response, several hundred genes are 
involved and a process to achieve pathogen clearance and at the same 
time avoid consequences of dysregulated gene expression must be 
tightly regulated. Recent studies have shown several miRNAs, such as 
miR-155, miR-146, and miR-223, regulate the acute inflammatory 
response after the recognition of pathogens by the Toll-like receptors 
(TLRs) [85-88].  
miRNA and Macrophage/Monocytes. To examine the potential 
involvement of miRNAs in regulation of the innate immune response, 
Taganov et al.  analyzed expression of 200 miRNAs after exposure of 
human monocytic THP-1 cell line to LPS [85]. They showed three 
miRNAs were up-regulated, namely miR-146, miR-132, and miR-155. 
Further, induction of miR-146 by the TLR system displayed dual 
occurrence: TLRs that recognize bacterial constituents and reside on the 
cell surface (like TLR2, TLR4, and TLR5) trigger miR-146 induction; 
those TLRs that mainly sense viral nucleic acids and localize 
intracellulary (TLR3, TLR7, and TLR9) have little effect on miR-146 
expression.
 
Figure 8 - Overview of the role of miRNAs during the differentiation and 
maturation of immune cells. miRNAs have been shown to regulate multiple steps 
in the development of immune cells including lymphocytes (B and T cells) and 
myeloid cell (monocytes and neutrophils). CD, cluster designation; CLP, common 
lymphocyte progenitor; CMP, common myeloid progenitor; GMP, granulocyte 
monocytic progenitor; HSC, hematopoietic stem cell; MDP, myeloid dendritic 
progenitor. From Mark A. Lindsay (2008). microRNAs and the immune response. 
Trends in Immunology Vol.29 No.7:343-351. 
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Promoter analysis of the miR-146a revealed that it is regulated by NF-
!B and may function as a negative regulator of IRAK1 (IL-1 receptor-
associated kinase 1) andTRAF6 (TNF receptor-associated factor 6) 
expression [85].  As it is well known that TRAF6 and IRAK1 are two 
key adapter molecules in the downstream of TLRs, which can trigger 
the activation of I!B kinase (IKK) and the Jun kinase (JNK), then in 
turn, activate NF-!B and activating protein (AP)-1 transcription factors, 
and finally result in up-regulation of immune-responsive genes [89]. In 
addition to TLRs stimulations, Perry’s study verified miR-146a 
expression was related to IL-1b-induced responses [88]. They 
demonstrated an important feedback mechanism during severe 
inflammation: IL-1b-induced increases in miRNA-146a expression 
negatively regulate IL-8 and RANTES release. Recent study found this 
miRNA to be associated with psoriasis, a chronic inflammatory skin 
disease, indicating that alterations in the fine-tuning of innate immune 
responses by miRNAs may contribute to inflammatory disorders[90].  
Taken together, miR-146a now was thought to be a negative regulator 
during the innate immune responses. Moschos et al. measured the 
differential mature miRNA expression profile during the innate 
immune response to aerosilized LPS in the mouse lung [91]. They found 
12 miRNAs (miR-21, -25, -27b, -100, 140, -142–3p, -181c, 187, -194, -
214, -223, and -224), which were involved in the innate immune 
response, were significantly up-regulated in a time dependent fashion. 
Unlike the LPS-induced response in THP-1 cells and mouse 
macrophages  expression of miRNA-146 or -155 were not found to 
upregulate[85,86]. They speculated the reasons behind these differences 
could be a result of multiple factors including the presence of multiple 
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cell types within the lung or be related to the dynamics of the two 
models. 
miRNA and Granulocyte. miRNA-223 was found to have crucial roles 
in regulating granulocyte proliferation and activation. Its expression 
was bone marrow-specific and was confined to myeloid cell lineages[92].  
However, overexpression of miR-223 and knock-down of miR-223, 
studied by two independent groups, showed the opposite effects [93,94]. 
Fazi et al. firstly reported that miR-223 was a positive regulator of 
granulocyte differentiation by both overexpression and knock-down 
experiments. In their study, two transcription factors named NFI-A 
(nuclear factor I-A) and C/EBP" (the CCAAT enhancer proteins), had 
been implicated to regulate miR-223 expression. These two factors 
compete for binding to the miR-223 promoter. NFI-A is required to 
maintain miR-223 at low levels, then during differentiation NFI-A is 
replaced by the transcription factor C/EBP", which induces high 
expression of miR-223 [93]. This, in turn, represses the expression of 
NFI-A post-transcriptionally. The role of C/EBP" in regulating miR-
223 expression was confirmed by Fukao et al., who demonstrated 
C/EBP" can combine with PU.1 (another myeloid specific transcription 
factor) to enhance the promoter activity[95]. More recently, observations 
in miR-223 knockout mice revealed the negative role of miR-223 in 
regulating progenitor proliferation and granulocyte differentiation and 
activation[94]. They also found a critical target of miR-223 in early 
myeloid progenitors, Mef (myeloid ELF-1-like factor) 2c, a 
transcription factor that promotes myeloid progenitor proliferation, or 
the insulin-like growth factor receptor (IGFR). Although paradoxical 
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results exit, the role of miR-223 in regulating granulocyte production 
and the inflammatory responses was indispensable.  
 
1.5.2 miRNAs in the Adaptive Immune Responses 
In addition to regulating innate immune responses, miRNAs also have 
an important role in modulating adaptive immune responses, a central 
feature of which was activation and subsequent clonal expansion of 
antigen specific lymphocytes. 
miRNA and T Cell Differentiation and Activation. In mice with a 
deficiency in Dicer in early T-cell progenitors (under the lck-driven cre 
transgene) the percentages of different double-negative, double-positive 
and the CD4–CD8 lineage (i.e. whether the transitioning cells became 
CD4 or CD8 single-positives) decisions also appears to be intact, albeit 
with a 10-fold reduction in total thymocyte numbers past the double-
negative stage[96]. Instead, later deletion of Dicer with a CD4-drive cre 
transgene results in smaller reductions in the number of total 
thymocytes, at the single- positive stage[97]. Although the precise 
molecular mechanism for the discrepancy between these studies is still 
not well characterized, the differential response in the numerical impact 
on T-cell differentiation depending on the timing of Dicer excision 
suggests that miRNA do not have a non-redundant role in any specific 
developmental event, but rather create a delayed numerical reduction as 
the result of diminished proliferation and increased susceptibility to cell 
death[96,97]. Dynamic regulation of miRNA expression in several distinct 
stages of T cell was observed by Neilson et al. [98].  They found the 
degree of miRNA variation, across the T-lymphocyte developmental 
progression is striking, suggesting global miRNA levels are correlated 
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to the level of T cell differentiation. Recently, the miRNA expression 
profile in antigen-specific naïve, effector and memory CD8 T cells was 
analyzed using three different methods[99]. Among miRNAs, expressed 
in all the T cell subsets, the frequency of seven miRNAs (miR-16, miR-
21, miR-142-3p, miR-142-5p, miR-150, miR-15b, and let-7f) alone 
accounted for 60% of all miRNAs. Compared with naïve cells, global 
downregulation of miRNAs (including six out of the seven dominantly 
expressed miRNAs) was observed in effector T cells, and in memory T 
cells the miRNA expression levels tended to come back up though they 
were still lower than in naïve cells. It seemed that the level of most 
miRNAs expression appear to inversely correlate with the activation 
status of the cells, exception of miR-21. Since regulation of miRNA 
expression was found to characterize the stage-specific development of 
thymocytes, miRNAs may modulate the differentiation status of 
antigen-stimulated T cells[99].  As stated above, different development 
stages and cell types of T cells have distinct miRNA expression 
profiles. However, studies on the relationship between the expression 
and functions of these miRNAs are limited. In 2007, Li et al. 
demonstrated that TCR sensitivity and signalling strength can be 
modulate posttrascriptionally by miR-181a (figure 9)[100]. The 
expression of miR-181a is higher in immature T cell populations such 
as double positive DP thymocyres, but lower in the more differentiated 
T cell population such as Th1 and Th2 effectors cells. The inhibition of 
this miRNA significantly impairs DP cell sensitivity and efficiently 
obstructs positive and negative selection, whereas increasingly miR-
181 expression in mature T cells augments their sensitivity to peptide 
antigens[100]. Moreover, quantitative regulation of T cell sensitivity by 
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miR-181a enables mature T cells to recognize antagonists-the 
inhibitory peptide antigens-as agonists. Mechanism study demonstrated 
that this did not result from changes in the expression of surface 
receptors but instead involved the coordinated down regulation of 
multiple phosphatases. Multi-target regulation by miR-181a is required 
for fine-tuning T cell sensitivity, thus, miR-181a was thought an 
intrinsic modulator of T cell sensitivity and selection [100].  In addition, 
Neilson et al. also proved miR-181a was involved in positive selection 
of T cell through repressing the expression of BCL-2, CD69, and the T 
cell receptor [98].  These findings suggest that further characterization of 
the molecular networks controlled by miR-181a would probably yield 
additional insights about other possible functions for miR-181a in 
adaptive immune responses.  
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miRNA and B Cell. The essential role of miRNA in B-cell 
differentiation was first revealed in mice with a haematopoietic defect 
in Ago2, encoding an Ago protein indispensable for miRNA biogenesis 
and function[101]. Deficiency of Ago2 did not affect the generation of 
early pro-B cells, but significantly impaired further pre-B-cell 
differentiation and the succeeding peripheral B-cell generation. In 
agreement with this, a subsequent study where the whole miRNA 
network was ablated by employing the B-cell-specific deletion of a 
conditional allele of Dicer has demonstrated that B-cell differentiation 
is almost completely blocked at the pro- to pre-B-cell transition, at least 
partially as a result of the deregulation of a pro-apoptotic molecule, 
Bim[102]. Moreover, Dicer deficiency in B cells also resulted in 
sustained terminal deoxynucleotidyl transferase expression throughout 
B-cell maturation, altering the generation of the antibody repertoire[102].  
 
Figure 9 -  Modulation of the antigen sensitivity of T cells by the miR-181a 
dimmer switch (or rheostat). The expression of miR-181a is regulated during T-
cell development and maturation, and the level of miR-181a expression correlates 
with T-cell sensitivity to antigens, suggesting that miR-181a might act as an 
intrinsic rheostat or dimmer switch to tune T-cell sensitivity to antigens during T-
cell development and maturation. (a) In mature effector T cells, microRNA-181a 
(miR-181a) is expressed at low levels and therefore the signalling rheostat is tuned 
to high resistance. That is, by decreasing miR-181a expression and de-repressing 
the negative signals that are controlled by the negative regulators of T-cell receptor 
(TCR) signalling (such as SH2 (SRC homology 2)-domain-containing protein 
tyrosine phosphatase 2 (SHP2), protein tyrosine phosphatase, non-receptor type 22 
(PTPN22), dual-specificity protein phosphatase 5 (DUSP5 and DUSP6) the signal 
output, such as T-cell proliferation and cytokine secretion induced by peptide–
MHC complexes, is dramatically reduced or completely turned off. (b)  By contrast, 
in immature T cells, such as CD4+CD8+ thymocytes, miR-181a is expressed at high 
levels and thus the rheostat is tuned to low resistance. That is, by increasing 
miRNA expression and repressing the negative signals that are controlled by the 
negative regulators of TCR signalling, the signal output from the identical 
stimulation is dramatically enhanced. From Lodish et al. (2008). Micromanagement 
of the immune system by microRNA. Nature Reviews Immunology, 8: 120-130. 
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Whereas these findings provided important insights as to how the 
miRNA network could impact B-cell differentiation and function, 
recent studies have begun to explore the role for individual miRNA in 
controlling different aspects of B-cell biology. 
Similar to miR-181a, miR-150 also shows a temporo-spatial expression 
pattern during the development of B cell [103-106]. High-level expression 
of miR-150 in the spleen and the thymus suggested that it might 
participate in B and/or T lymphopoiesis. Indeed, over expression of 
miR-150 in haematopoietic stem cells blocked B lymphopoiesis by 
inhibiting the transition from the pro-B to the pre-B cell stage and 
greatly impaired the formation of mature B cells, but had little effect on 
the formation of either mature CD8- and CD4-positive T cells or 
granulocytes or macrophages [106].  This observation was consistent with 
another study, which also proved the importance of miR-150 in B cell 
formation using gain- and loss of function mouse models [104].  Further, 
Xiao et al. demonstrated a transcript factor-Myb, which is highly 
expressed in lymphocyte progenitors, might be a crucial target of miR-
150. Transgenic mice lacking c-Myb looked very similar to the 
transgenic mice with ectopic expression of miR-150 in the progenitors-
abnormal B cell development and whole sale loss of B1 cells [107]. 
Although Myb has a key role in both B cell and T cell development, 
over expression or deletion of miR-150 in mice affects only the 
development of B cells, but not T cells.   
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1.5.3 miRNA-155: a regulator of B - and T-cell maturation 
and the innate immune response 
MiR-155 represent a typical multifunctional miRNA. To date, 
increased evidence points out that miR-155 is involved in numerous 
biological process including haematopoiesis, inflammation and 
immunity. Deregulation of miR-155 has been found to be associated 
with different kinds of cancer, cardiovascular disease and viral 
infections.  
MiR-155 is processed from an exon of non-coding RNA transcribed 
from BIC, the B-Cell Integration Cluster located on chomosome 21. A 
central role for miR-155 in the regulation of T- and B cells responses 
during the acquired immune response has emerged from studies in 
knockout mice;  Rodriguez et al. found these mice are immunodeficient 
and fail to develop protective response to virulent Salmonella 
typhimurium infection after immunization with a non-virulent strain of 
these bacteria. As for B-lymphocytes, immunized knockout mice 
produced significantly reduced amounts of IgM and switched antigen-
specific antibodies, indicative of impaired B cell responses [108,109]. 
Interestingly, miR-155 knockout mice also undergo age-related lung 
airway remodelling, which is characterised by increased collagen 
deposition, smooth muscle mass and inflammatory cell infiltrate within 
the broncholaveolar lavage [108]. These phenotypic observations seem to 
be in part mediated through involvement of miR-155 in B-cell 
production of isotype-switched, high affinity IgG1 antibodies and 
during the development of B cell memory[109,110]. The observed 
reduction in the size of the germinal centers suggested that reduced 
IgG1antibody production and B-cell memory was the result of a failure 
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to select high affinity plasma B cells [109,110]. Examination of the 
mechanism showed that miR-155 attenuated the expression of the 
transcription factor PU.1, which was shown to down regulate IgG1 
levels [110]. In addition, miR-155 targets the cytidine deaminase AID, a 
critical enzyme that mediates class-switch recombination and somatic 
hypermutation [111,112]. These AID studies have used mutant mice in 
which the miR-155 binding site in the 3! UTR of AID is abolished.  
As with B cells, miR-155 seems to be involved in T cell differentiation 
[108,109]. Thus, naïve T cells derived from miR-155 knockout mice were 
shown to have an increased propensity to differentiate into Th2 rather 
than Th1 cells, with the concomitant production of Th2 cytokines such 
as IL-4, IL-5 and IL-10 [108,109]. It has been speculated that this results 
from miR-155 targeting of c-Maf (musculoaponeurotic fibrosarcoma), a 
transcription factor that is known to be a potent transactivator of the IL-
4 promoter, a key cytokine in the development of Th2 cells [108]. With 
regard to the acute immune response, the T lymphocytes had an 
impaired response and showed attenuated IL-2 and interferon # (IFN#) 
release in response to antigens (figure 10)[108,109]. 
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In monocytes, macrophages and myeloid dendritic cells, miR-155 
increases substantially after exposure to a variety of inflammatory 
stimuli [86,113,114]. Direct recognition of microbial products by Toll-like 
receptors, particularly pathogen-associated molecular motifs derived 
from bacteria or viruses, leads to miR-155 upregulation. Furthermore, a 
plethora of immunoregulatory cytokines, such as tumor necrosis factor 
and interferons, also induce miR-155 upregulation in macrophages. A 
link between miR-155 and the innate immune response was suggested 
from studies showing increased expression after LPS (via TLR-4) and 
lipoprotein (via TLR- 2) stimulation in monocytes or macrophages and 
in the splenocytes of mice that had been inoculated with Salmonella 
enteritidis–derived LPS [86,87]. Increased miR-155 expression was also 
seen after activation of the innate response by viral- and bacterial-
derived nucleotides including poly (I:C) (via TLR-3) and CpG 
(viaTLR-9), although increased expression in response to IFN$ and 
IFN# seemed to be secondary to the autocrine release of TNF-" [86]. 
Tili et al.  showed the relationship between miR-155 and TNF-" that is 
the main cytokine produced by macrophages in response to LPS.  
They found the level of miR-155 in macrophage oscillated rapidly 
following TNF-" stimulation, which is similar to the oscillatory activity 
of NF-!B.  
 
Figure 10 – Role of miR-155 in lymphocyte development. miR-155-null mice are 
characterized by complex defects in homeostasis of the immune system and 
globally impaired immune responses. Among the defects that were characterized in 
detail, the loss of miR-155- mediated inhibition of the transcription factor cMAF 
led to increased production of interleukin4 (IL-4) and T helper-2 (Th2) cells. The 
germinal centre reaction was disrupted, resulting in impaired T cell-dependent 
antibody responses. Modified from Stefani et  al. (2008). Small non-coding RNAs 
in animal development. Nature Reviews Molecular Cell Biology 9, 219-230. 
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This implied miR-155 might exert both positive and negative effects by 
acting post-transcriptionally to regulate expression of different target 
proteins, such as, FADD (Fas-associated death domain) and Ripk1 
(receptor interacting serine-threonine kinase 1). Further, miR-155 was 
found to enhance the production of TNF-", which suggested the 
positive role of miR-155 to regulate the release of inflammatory 
mediators during the innate immune response. This hypothesis is 
supported by the results of an array analysis of gene expression in the 
Eµ-miR-155 transgenic mice that over-expressed miR-155 in B cells, 
which demonstrate an elevated level of serum TNF-" [87]. 
Interestingly, a recent report has shown that LPS induced strong but 
transient miR-155 expression in mouse bone marrow cells and 
indicated that this is likely to drive granulocyte/monocyte expansion 
[115]. The possible involvement of miR-155 in the development of acute 
myeloid leukaemia (AML) was revealed from studies of the effect of 
long-term miR-155 over expression. In these studies, viral mediated 
transfection of miR-155 into haematopoietic stem cells (HSCs) and 
engraftment into lethally irradiated mice produced some of the 
pathological features characteristic of myeloid neoplasia [115]. This led 
these authors to speculate that the well-established link between 
inflammation and cancer might involve chronic up-regulation of miR-
155, which could predispose these individuals to the development of 
myeloproliferative disorders. The pro-inflammatory transcription 
factors, AP-1 and NF-!B, have both been reported to regulate miR-155 
expression [109,86,117].Thus, in macrophages, the action of TLR-3 and 
TNF" is mediated via AP-1[86], whereas the response to LPS is via NF-
!B [116]. Similarly, BCR cross-linking in a human B-cell line was shown 
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to induce miR-155 expression via activation of the extracellular-
regulated kinase (ERK) and c-jun N-terminal kinase (JNK) pathway 
and the subsequent recruitment of FosB and JunB to AP-1 binding site 
[117]. 
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1.6 Aim 
Recently, it has become evident the importance of miRNAs in 
regulating immune response, as well as immune cell development. 
During my phD fellow I focused my attention on the relationship B-
lymphocytes-microRNA; in particular I examined two the different 
topics: the  microRNA activation in response to oncogenic virus 
infection and cloning of new microRNA within IBTK gene located in 
the genomic sequence 6q14.1, which is a hot spot of chromosomal 
rearrangements in lymphoproliferative disorders. 
Epstein–Barr virus (EBV), which infects over 90% of the adults, 
appears to have evolved to exploit the normal biology of B-cell 
development in order to persist as a life-long asymptomatic infection. 
However, EBV can contribute to oncogenesis. Indeed, it is frequently 
found in Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopharyngeal 
carcinoma and lymphoproliferative diseases in immunesuppressed  
individuals [118,119]. EBV-related oncogenesis is principally associated 
with latency during which only a limited subset of the full repertoire of 
viral genes are transcribed. Of the genes expressed during viral latency 
in EBV-associated diseases, LMP1 is the one most implicated in tumor 
formation[120,121]. LMP1 is invariably expressed in Burkitt’s lymphoma, 
it is required for EBVmediated transformation of lymphocytes in vitro 
and it transforms rodent fibroblasts. LMP1 is a six-transmembrane 
constitutively active signaling molecule that functionally mimics 
members of the cellular tumor necrosis factor receptor (TNFR) family. 
While the transmembrane domains are required for aggregation and 
constitutive activation of LMP1[122-125], two cytoplasmic domains, i.e. 
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the C-terminal activator regions 1 and 2 (CTAR-1 and -2), are critical 
for the transforming properties of LMP1[126-129].  
Together, these signaling domains act through cellular TNFR-
associated factors (TRAFs) and other cell-signaling molecules to 
activate, three transcription factors, namely, nuclear factor-!B (NF-
!B), activator transcription factor-2 (ATF)-2 and AP-1, via c-Jun N-
terminal kinase (JNK)[125-129]. As mentioned above miR-155 plays a 
critical role in lymphocyte activation in vivo[108,109] and is induced by a 
variety of immune cell stimuli, i.e. toll-like receptor (TLR) ligands, 
TNF-", interferon-beta (IFN-$) and antigens [B-cell receptor (BCR) 
engagement][130]. The mechanism by which miR-155 is regulated after 
TLR and IFN signaling in macrophages is still unknown. Here we show 
that LMP1 upregulates the expression of miR-155 mainly by activating 
the NF-!B pathway, which suggests that miR-155 can cooperate in the 
EBV-mediated transformation of B cells. 
Quinto and Scala lab have recently characterized the Inhibitor of 
Bruton’s tyrosine kinase (IBtk) gene (accession number AL050333) 
that encodes three adaptor proteins in cell signalling [131]. The IBTK 
gene is 77,58 Kb and includes 29 exons with two promoters and 
transcriptional start sites that result in the expression of three IBTK 
transcripts, named IBTK" , IBTK$  and IBTK# [131]. IBtk# has been 
characterized as a ligand inhibitor of Tec kinases, such as Btk, Itk, and 
Akt, which regulate signal transduction upon specific stimuli [131,132]. As 
inhibitor of proliferation, IBTK is a candidate tumor suppressor gene. 
Consistently, the human IBTK gene is located in the genomic sequence 
6q14.1, which is a hot spot of chromosomal rearrangements in 
lymphoproliferative disorders[133]. In this study, we have addressed 
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whether the IBTK gene might play a role in transcription regulation as 
source of miRNAs. By bioinformatics analysis, we identified four 
putative precursors of miRNA (pre-miR) encoded by three distinct 
introns and the 3’ un-translated region (3’UTR) of the IBTK gene. Of 
them, only the pre-miR-IBTK3 encoded by intron 26 occurred in vivo, 
and was the effective substrate of RNase III Dicer. The presence of 
homologous in other primates suggests an evolutionary conserved role 
of pre-miR-IBTK3. Based on this evidence, IBTK miRNA is a novel 
member of the wide miRNAs genomic network. 
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Chapter 2: MATERIALS AND METHODS 
 
2.1 Cell culture  
EBV-negative human B cells (DeFew) and EBV immortalized human 
B cells MC3 (kindly provided by Prof. Giuseppe Scala, University 
‘Magna Grecia’ Catanzaro) Devozione, Cap (kindly provided by Dr 
Giuseppina Ruggiero, University ‘Federico II’, Naples), were cultured 
in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% fetal bovine serum (Invitrogen) and 2mM glutamine. Murine 
embryonic fibroblasts (MEFs) and HEK 293 referred to as LinX, stably 
transfected with the helper vector, [LinX cell line, Open biosystem, 
(http://www.openbiosystems.com/RNAi/LinX/)] were cultured in 
DMEM medium (GIBCO-Invitrogen) supplemented with 10% fetal 
bovine serum (Invitrogen) and 2mM glutamine. 
Human peripheral blood mononuclear cells (PBMCs) were isolated by 
Ficoll Paque gradient (GE Healthcare Europe, Munich, Germany) from 
buffy coats. Healthy subjects blood was diluted 1:1 in PBS and 
stratified on Ficoll solution with a 3:1 v/v ratio. After 30 min 
centrifugation at 1200 x g, PBMCs were recovered and resuspended in 
RPMI-1640 medium supplemented with 10% FCS. 
 
2.2 RNA preparation and northern blot 
Total RNA was extracted using Trizol reagent (Invitrogen) according to 
supplier’s protocol. Northern blot analysis was carried out on 15 µg of 
total RNAs. Briefly, all RNA samples were dissolved in loading buffer 
[0.05% bromophenol blue, 0.05% cyanol, 5% Ficoll (type 400), 80% 
formamide and 7M urea], boiled for 5 min at 95°C and loaded onto 
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15% polyacrylamide gel under denaturizing conditions [15% 
acrylamide-bisacrylamide 19/1, 45mM Tris, 45mM boric acid, 1Mm 
EDTA pH 8, 7M urea, 0.01% N,N,N’,N’-tetramethylethylenediamine 
(TEMED) and 0.1% ammonium persulfate (APS)]. Samples were 
resolved by electrophoresis for 90 min at 150V and transferred onto 
nylon membranes (Hybond N+, Amersham/GE Healthcare, Little 
Chalfont, UK) by capillary blot. The nylon membranes were then 
equilibrated in 1M NaCl and pre-hybridized in 6X SSC, 5X Denhart’s 
solution (1X Denhart’s solution= 0.1% Ficoll, 0.1% polyvinyl 
pyrrolydone and 0.1% bovine serum albumin), 5 mg/ml of sheared 
salmon sperm ds-DNA (Ambion, Austin TX, USA) at 42 °C for 2 h. 
After pre-hybridization, 1x106 CPM/ml of [#32P-ATP] radiolabeled 
oligonucleotide probe was added and the hybridization carried out 
overnight at 42 °C. The membranes were washed twice in 2X SSC, 1% 
SDS at 42°C for 30 min and exposed either by autoradiography or by 
phosphorimage screen (Amersham/GE Healthcare). The signals were 
quantified with image-scanning or by Image-J software analysis. 
For Northen Blot in figure 24, the nucleotide sequence of probes was as 
follows:  
IBTK1-25, for the nucleotides 1-25 of predicted pre-miRIBTK3 
5’-TGGTAGTAAAATGATGAGCAAAGAC-3’;  
IBTK26-50, for the nucleotides 26-50 of predicted pre-miR-IBTK3, 5’-
ACATGCCAGAAGCTAATATGAACAC-3’;  
IBTK51-75 for the nucleotides 51-75 of predicted pre-miRIBTK3 
5’-TCACCAGACTCACTGAGCACCCAAT-3’;  
IBTK76-100, for the nucleotides 76-100 of predicted pre-miR-IBTK3  
5’-AATTTCAATTAATTTACTCATTCAT-3’. 
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2.3 Western blot analysis  
The cell pellets were resuspended in 1ml of lysis buffer [10mM 
HEPES, pH 7.4, 150mM KCl, 1mM EDTA pH 8,1% Triton X-100, 
1mM DTT, 1mM orthovadanate, 1mM NaF and protease inhibitor 
cocktail (Roche, Basel, Switzerland)] at 4°C for 20 min. Then, 40 µg of 
proteins, of each sample, were resuspended in Laemmli buffer[134] and 
resolved by SDS–PAGE (running gel: 0.4M Tris, pH 8.8, 12% 
acrylamide/bis-acrylamide 37/1, 0.1% SDS, 0.01% TEMED, 0.1% 
APS; staking gel: 0.07M Tris pH 6.8, 5% acrylamide/bis-acrylamide 
37/1, 0.1% SDS, 0.01% TEMED, 0.1% APS). The proteins were 
transferred onto nitrocellulose membranes (Hybond ECL, Amesham/ 
GE Healthcare) by electroblotting. Membranes were blocked in 5% of 
‘non-fat milk’ (BioRad, Hercules CA, USA) 0.5% BSA in phosphate 
buffer solution for 2 h at room temperature and immunoblotted with 
monoclonal antibody against LMP1 (kindly provided by Dr Dong Yun 
Lee, McArdle Laboratory for Cancer Research, University of 
Wisconsin-Madison), mouse polyclonal antibody against #-tubulin 
(Sigma Chemical Company, St Louis MO, USA) mouse monoclonal 
antibody against p65 (SantaCruz, CA, USA), rabbit polyclonal 
antibody against IkB" (SantaCruz), rabbit polyclonal against H3 
(SantaCruz) or rabbit polyclonal antibody against PU.1 (Santa Cruz). 
Specific secondary antibodies (Sigma Chemical Company), horse-
radish peroxidase conjugated, were used for protein detection by 
enhanced chemiluminescence (ECL, Amesham/GE Healthcare) 
followed by autoradiography (Hyperfilm ECL, Amesham/GE 
Healthcare). We used the Image-J software for densitometric analysis. 
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2.4 Cloning and mutagenesis of BIC/miR-155 promoter 
The human BIC/miR-155 promoter region extending from 1783 to 1, 
from 1380 to 1, from 1065 to 1 relative to the start site was isolated 
from MC3 genomic DNA by PCR using the following primers: 
Fw AGCTGAGCTCGAAAGGTCACCCTAGAATTG 
(-1783), 
Fw AGCTGAGCTCGATCTGGCACATGGTAAATG  
(-1380), 
Fw AGCTGAGCTCCAGTCACATGTTGATGAGGC  
(-1065), 
Rev CATGAAGCTTATCCGCTCCCTTCCCGAG (+1). 
The isolated fragments were digested with SacI and HindIII and cloned 
into SacI and HindIII cut pGL3basic (Promega, Madison, WI, USA). 
The entire promoter region was sequenced and no discrepancies were 
identified relative to the Genebank genomic sequence 
(http://www.ncbi.nlm.nih.gov/GenBank). Mutagenesis of the pLuc1380 
and pLuc1783 reporter plasmid was carried out with the ‘Expand Long 
Template PCR system’ (Roche) and the  oligonucleotides listed belove. 
NF-!B1: 
Fw 5’-GTAAATTAAGTACTATGCTCGAGCCAGCTCTGACATG-
3’; 
Rev 5’-CATAGTACTTAATTTACAGATGGCTCAGGTTGGTTAAG 
-3’. 
NF-!B2: 
Fw 5’CAACCTAGAATGAGAAATGCTCGAGTCAGAAAGGC 
ATTGTAGG-3’  
Rev 5’-CATTTCTCATTCTAGGTTGAACTATACCTCCCTT 
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CTCCCAG TG-3’  
AP-1: 
Fw 5’-GGCGCCTGGTCGGTTATCTCGAGCAAGTGAGTT 
ATAAAA-3’; 
Rev  5’-ATAACCGACCAGGCGCCT TTTCTGCAACCC-3’; 
In each case, the core transcription factor binding site was replaced by a 
XhoI restriction site. Mutations were initially screened by digesting 
with XhoI and then verified by sequence analysis. 
 
2.5 Reporter analysis 
For each reporter plasmid, 2x106 MEFs were distributed in 6 cm dish 
plates containing 5ml RPMI1640 (Invitrogen) 10% FBS (Cambrex, 
East Rutherford, NJ, USA), 2mM glutamine. FuGene (Roche) of 6 µl 
were added to 300 µl of DMEM and incubated for 5 min at room 
temperature. Each reporter vector of 0.5 µg plus 0.2 µg of $-
galactosidase vector were then added to the mixture, the tubes were 
shacked and incubated at room temperature for 15 min. For each 
transfection, the mixtures were then added to each plate and plates were 
incubated at 37°C, 5% CO2 for 48 h. Cells were harvested 48 h later 
and assayed for luciferase activity. Results are presented as average of 
three independent experiments. For each reporter plasmid, 2x106 
DeFew were distributed in 6 cm dish plates containing 5ml RPMI1640 
(Invitrogen) 10% FBS (Cambrex), 4mM glutamine. FuGene (Roche) of 
8 µl were added to 300 µl of DMEM and incubated for 5 min at room 
temperature. Each reporter vector of 1µg plus 0.5 µg of $-galactosidase 
vector were then added to the mixture, the tubes were shacked and 
incubated at room temperature for 15 min. For each transfection, the 
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mixtures were then added to each plate and plates were incubated at 
37°C, 5% CO2. After 6 h each sample was split in two, and one of them 
was treated with 10 ng/ml of phorbol myristoylated acetate (PMA). 
Cells were harvested 48 h later and assayed for luciferase activity. 
Results are presented as average of three independent experiments. 
 
2.6 Chromatin immunoprecipitation assay 
MC3 or DeFew cells (5x106 cells) were exposed to 1% formaldehyde 
for 10 min at 37°C to obtain protein–DNA cross-linking. The nuclear 
fraction was sonicated to yield chromatin fragments of 200–1000 bp; 
5% of the total volume was removed from each sample and used as the 
input fraction. Chromatin was pre-cleared by pre-incubation with a 
DNA salmon sperm/protein A-agarose 50% slurry (Upstate, Temecula, 
CA, USA) for 1 h at 4°C. The agarose was centrifuged, and the pre-
cleared chromatin supernatant was incubated with the antibodies (3 µg) 
against RNA pol II (mAb anti RNA polymerase II, Active Motif, 
Rixensart, Belgium), p50 or p65 (pAb anti p50 or pAb anti p65, kindly 
provided by Dr N. Rice, Frederick Cancer Research and Development 
Center, Frederick, MD, USA), against histone 3 (pAb anti H3, 
SantaCruz), overnight at 4°C. The protein–DNA-antibody complexes 
were collected by the addition of the salmon sperm DNA– protein A-
agarose (2 h at 4°C) and washed, and protein– DNA cross-linking was 
reversed (4 h at 65°C). DNA was purified by phenol/chloroform 
extraction and ethanol precipitationand aliquots (25%) of the purified 
materials underwent PCR (5 min at 94°C, 1 min at 94°C, 1 min at 
52°C, 1 min at 72°C for 40 cycles, 5 min at 72°C). 
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2.7 Preparation of nuclear extracts and electrophoresis 
mobility shift assay 
MC3 cells (5- to 6x106 cells) were washed with cold phosphate 
buffered saline and harvested. The cell pellet was resuspended in 
extraction buffer containing 10mM HEPES, pH 7.9, 10mM KCl, 
1.5mM MgCl2, 0.1mM EGTA, 0.5mM DTT, 0.5mM PMSF, 10 µg/ml 
aprotinin, 10 µg/ml leupeptin, passed through a needle, kept on ice for 
45 min, and centrifuged (15 min at 14 000 r.p.m. at 4°C). The nuclear 
pellet was then resuspended in high salt extraction buffer containing 
10mM HEPES, pH 7.9, 0.4mM NaCl, 1.5mM MgCl2, 0.1mM EGTA, 
0.5mM DTT, 0.5mM phenylmethylsulfonyl fluoride, 10 µg/ aprotinin, 
10 µg/ml leupeptin and incubated for 45 min at 4°C. The nuclear 
extract supernatant was obtained by centrifugation (30 min at 14 000 
r.p.m. at 4°C), protein concentration was determined and 5 µg aliquots 
were stored at -80°C until used. Double-stranded synthetic 
oligonucleotides were radiolabeled using [#32P]ATP (3000 Ci mmol–1; 
Amersham Biosciences) and T4 polynucleotide kinase (Fermentas, 
Burlington, ON, Canada). The binding reaction was carried out for 20 
min at room temperature with 5 µg of nuclear proteins in 10% glycerol, 
60mM KC1, 1mM EDTA, 1mM dithiothreitol and 0.25 µg/µl poly[dI–
dC] containing 50.000 cpm of radiolabeled probe and a 80-fold molar 
excess of unlabeled competitor oligonucleotide when indicated. For 
supershift experiments, 4 µg of specific anti-p65 or anti-p50 were 
added to the binding reaction and incubated for 30 min, after which we 
added the radiolabeled probe. DNA–protein complexes were separated 
by 5% non-denaturing polyacrylamide gel and revealed by either 
autoradiography or phosphorimage screen (Amersham Biosciences). 
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2.8 Transient transfection 
DeFew cells (3x106 cells) were centrifuged, washed in PBS and 
resuspended in 300 µl of electroporation medium (RPMI 1640 medium, 
20% FBS and 2mM Glutamine). Cells were mixed with 20 µg of 
plasmid expressing LMP1 (pcDNA3-LMP1), or LMP2 (pcDNA3-
LMP2) or both and subsequently transferred in electroporation cuvette. 
Cells were electroporated twice at 220 V, 960 µFa and incubated 5 min 
on ice. Cells were plated in 10 ml of RPMI 1640 medium, 10% FBS 
and 2mM glutamine for 2 days. After 2 days, they were harvested and 
assayed for miR-155 and LMP1 expression. 
 
2.9 Viral generation, infection and time course 
The retroviral vector LMP1pBABE-puro was kindly provided by Prof. 
Eiji Hara (University of Tokushima, Japan). LinX cell line, stably 
transfected with the helper vector, were grown in DMEM medium 10% 
FBS, 2mM glutamine and 100 µg/ml hygromicin. Transfections with 
LMP1pBABEpuro or pBABEpuro (empty vector) were as follows: 6 
cm plate of semi-confluent (about 1x106 cells) cells were transfected 
and 7.5 µg of DNA vector incubated in 20 µl of FuGene and incubated 
in 4 ml of medium without antibiotic for 24 h. After incubation, the 
medium was harvested, replaced with 4ml of fresh medium and the 
LinX cells incubated for 24 h for a second round of viral generation. 
DeFew cells (4x106 cells) were centrifuged, washed in PBS and 
resuspended in 4 ml of virus containing medium plus 4 µg/ml of 
Polybrene (Sigma). The infection was performed by spinoculation, 
namely by centrifugation at 3500 r.p.m. for 90 min at 20°C. After 
centrifugation, the cells were resuspended in 10 ml of RPMI and 
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incubated at 37°C, 5% CO2. Twenty-four hours later, the cells 
underwent a second round of infection. After 48 h, cells were treated 
with 1 µg/ml of puromicine to start selection of positive clones. For the 
time course, DeFew cells (4x106 cells) were centrifuged, washed in 
PBS and resuspended in 12 ml of virus containing medium plus 12 
µg/ml of Polybrene (Sigma). The infection was performed by 
spinoculation, namely by centrifugation at 3500 r.p.m. for 90 min at 
20°C. After centrifugation, the cells were resuspended in 10 ml of 
RPMI and incubated at 37°C, 5% CO2. Twentyfour hours later, 1 µg/ml 
of puromocine was added to cells to start selection. Cells were 
harvested at 6, 24, 48 and 72 h after infection and assayed for miR-155 
and LMP1 expression. 
 
2.10 Transient transfection of MC3 
MC3 cells (3x106 cells) were centrifuged, washed in PBS and 
resuspended in 300 µl of electroporation medium (RPMI 1640 medium, 
20% FBS and 2mM glutamine). Cells were mixed in a tube with 20 µg 
of pRc/CMV-HAIkB"-S32/36A (kindly provided by Prof. Ileana 
Quinto, University Magna Grecia, Catanzaro) and subsequently put in 
electroporation cuvette. Cells were electroporated twice at 220 V, 960 
µFa and incubated 5 min on ice. Cells were plated in 10 ml of RPMI 
1640 medium, 10% FBS and 4mM glutamine for 2 days. After 2 days, 
they were harvested and assayed for miR-155, p65 and I!B" 
expression. 
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2.11 Prediction of potential miRNAs 
Search for putative miRNAs generated by the genetic locus IBTK was 
performed by Pro-MirII software (http://cbit.snu.ac.kr/~ProMiR2/Index 
.php). The pre-miR-IBTK nucleotide sequences were predicted 
according to the following cut-off values: Window size: 100 base pairs; 
Shift size: 10 nucleotides; ProMir values: 0,017; Conservation score " 
0; Free Energy (%G) # -20; GC-ratio = 0.3-0.7; Entropy " 1.8. 
 
2.12 DNA plasmids 
To generate T7 expression plasmids of pre-miR-IBTK1, pre-miR-
IBTK2, pre-miRIBTK3 and pre-miR-IBTK4, the genomic DNA from 
MC3 cells was amplified by PCR with appropriate primers and cloned 
in the HindIII/XhoI-digested pcDNA3 vector (Invitrogen) under the T7 
promoter. The regions of the IBTK gene encompassed the nucleotides 
82971042-82970943 for pre-miR-IBTK1, the nucleotides 82963276-
82963177 for pre-miR-IBTK2, the nucleotides 82945044-82944945 for 
pre-miR-IBTK3 and the nucleotides 82937481-82937382 for pre-
miRIBTK4. 
Forward (FW) and reverse (RW) primers were as follows:  
pre-miR IBTK1 FW: 
5’-CCCAAGCTTTTGTATTGAAATGTCATAAAACC-3’;  
pre-miR IBTK1 RW: 
5’-GGCCTCGAGGGGAAAGTTAAATTTTTAAAATCA-3’;  
pre-miR IBTK2 FW: 
5’-CCCAAGCTTGAATGAAGCTACCCCCTTGCTTGG -3’;  
pre-miR IBTK2 RW 
5’-GGCCTCGAGGAGGGAGATAGTTCTTTGGGA-3’;  
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pre-miR IBTK3 FW: 
5’-CCCAAGCTTATATGTTCAATGAGAGCAAGG-3’;  
pre-miR IBTK3 RW: 
5’-GGCCTCGAGGAAACAAATGTTACTTGAAAC- 3’;  
pre-miR IBTK4 FW:  
5’-GGCCTCGAGGATTTTTAAAAAGCAACAAGAATC-3’;  
pre-miR IBTK4 RW:  
5’-GGCCTCGAGGCCGCCTGATAAATACTGTGGCCC-3’. 
 
2.13 Dicer RNase assay 
IBTK transcripts corresponding to predicted pre-miR IBTK were 
transcribed with T7 RNA polymerase and [32P]$-UTP (3000 Ci/mmol) 
using the Riboprobe System - SP6/T7 (Promega); ApaI-digested pre-
miR-IBTK pcDNA3 plasmids were used as template. RNA samples 
(106 cpm) were incubated with or without the recombinant human 
Dicer (2 Units) (Genlantis) in a reaction buffer (10 µl) containing 20 
mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mM 
ATP, at 37°C for 2 h. The RNA products were separated by 15% 
PAGE in 8M Urea TBE, and analyzed by autoradiography, as described 
[135]. 
 
2.14 Comparative analysis of nucleotide sequence 
The nucleotide sequence of Homo sapiens pre-mir-IBTK3 was aligned 
with the genome of Pan troglodytes, Pongo pygmaeus, Macaca 
mulatta, Bos taurus and Canis familiaris to identify homologous 
nucleotide sequences by BLAST software 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The pre-miR-IBTK3 
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homologues of Homo sapiens, Pan troglodytes, Macaca mulatta, Bos 
taurus and Canis familiaris were analysed for the identity percentage 
by CLUSTALW software (http://www.ebi.ac.uk/Tools/clustalw2/index 
.html) [136]. 
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Chapter 3: Epstein-Barr virus latent membrane protein 1 
trans-activates miR-155 transcription through the NF-!B 
pathway 
 
3.1 The expression of miR-155 is regulated by LMP1 
We measured miR-155 expression in three EBV immortalized cell lines 
(MC3, Devozione and Cap) and in two EBV-negative B-cell lines 
(EW36 and DeFew), a T-cell lymphoma cell line (Jurkat) and NB4 
from acute promyelocytic leukemia. As shown in figure 11, miR-155 
was expressed at relevant levels only in the EBV-positive cells 
according to Mrazek et al. [137]. In the EBV-negative B cells, miR-155 
expression was not affected by stable transfection of the EBV nuclear 
factor 2 (EBNA2) (figure 11), a viral transacting factor that activates 
the expression of such cellular and viral promoters as the HIV-1 long 
terminal repeat [138] and the interleukin-6 promoter [139].  
                           
Figure 11- miR-155 is upregulated in EBV-immortalized cell lines. Northern 
blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for 
the expression of mature miR-155 and normalized by the ubiquitous small nuclear 
RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not 
visible in this blot due to the brief exposure. 
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To evaluate whether LMP1 induces miR activation, we transiently 
transfected a vector expressing LMP1, LMP2 or both in DeFew cells 
(EVB-negative B cells). There was a 1.6-fold induction of miR-155 
expression in LMP1-transfected cells, no induction in LMP2-
transfected cells and a 1.7-fold induction in cells transfected with 
LMP1 and LMP2 (figure 12A and B). The significance of this finding 
is underestimated because only a few cells were transfected by LMP1 
expression vector. Indeed, LMP1 was much lower in transiently 
transfected DeFew cells than in MC3 cells (figure 12C). To overcome 
this problem, we infected the DeFew cells with a retroviral vector 
expressing LMP1 (pBABEpuroLMP1). As shown in figure 12D, we 
obtained a higher expression of LMP1, at 72 h post-infection, resulting 
in about 3.5-fold induction of miR-155 expression compared to DeFew  
cells infected with the empty virus (figure 12E and F). 
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3.2 miR-155 expression can be driven through activation of two 
NF-!B elements in the BIC/miR-155 promoter 
The foregoing results suggested that the LMP1-mediated induction of 
miR-155 occurred via a transcriptional mechanism. A recent study 
showed that the miR-155 promoter contains an AP-1 active site, located 
at 40 nt upstream from the TATA box and a NF-!B site located at 1150 
nt upstream from the transcription starting site [117]. The AP-1 active site 
plays a key role in activation of miR-155 expression induced by BCR 
[117]. To identify potential cis-elements active on miR-155, we isolated a 
promoter region of &1.9 kb of the BIC gene, which encodes miR-155 
[140], from MC3 cells and cloned it into a luciferase reporter plasmid. 
We looked for cis element homologies using TESS 
(http://www.cbil.upenn.edu/cgi-bin/tess) or TFSEARCH (http://www 
.cbrc.jp/research/db/TFSEARCH.html), and identified some potential 
transcription factor binding sites, among which, an additional NF-!B 
site located at 1697 nt upstream from the transcription starting site 
(figure 13).  
 
Figure 12 - LMP1 enhances the expression of miR-155 in an EBV-negative B-
cell line. (A) A representative northern blot analysis on total RNAs obtained from 
DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was 
analyzed for the expression of mature miR-155 and normalized by the ubiquitous 
small nuclear RNA (U6). (B) Graphic representation of the northern blot results as 
average of three independent experiments. (C) Western blot analysis of LMP1 
expression in the transfected cells compared to MC3 cell immortalized by EBV. 
Input proteins were equalized by detecting the endogeneous #-tubulin. (D) Northern 
blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with 
retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the 
expression of mature miR-155 and normalized by U6. (E) Graphic representation of 
the northern blot results as average of three independent experiments. (F) Western 
blot analysis of the expression of LMP1 upon infection with the retroviral vector. 
Input proteins were equalized by detecting the endogeneous  #-tubulin. 
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Figure 13 - The promoter of miR-155 encoding Bic gene contains two putative 
NF-!B binding sites. It is drown a partial nucleotide sequence of Bic promoter 
(from + 150 to – 222; from – 1064 to – 1912) containing the putative cis elements 
with higher score. The TATA box (-25 in pink), the AP1 site (-40 in red) the SP1 
site (- 97 in blue), the two NF-!B binding sites (-1150; -1697 in green), and the 
PU.1 site ( -1403 in purple). 
 
 
Because NF-!B signaling plays a central role in B-cell physiology, we 
focused on the two NF-!B cis-elements. We next examined by northern 
blot the induction of miR-155 expression in DeFew cells treated with 
PMA, which induces NF-!B by activating protein kinase C (PKC) and 
related phosphorylation of inhibitor-!Ba (I!B"), thereby leading to its 
degradation [141]. PMA (25 ng/ml) increased miR-155 expression by 
about 3-fold (figure 14A and B); miR-155 expression peaked 36 h after 
treatment and decreased thereafter (figure 14A and C). The latter 
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finding is in accordance with the pattern of PKC-activated NF-!B 
expression [141]. 
 
 
 
 
 
 
 
 
 
 
Figure 14 - PMA induces miR-155 expression in a dose- and time-dependent 
manner. (A) Left: northern blot analysis of RNAs from DeFew cells treated with 
different concentrations of PMA; Right: northen blot analysis of RNAs from 
DeFew cells at different times upon PMA treatment. The blots were analyzed for 
the expression of mature miR-155 and normalized by U6. (B and C) Graphic 
representation of the average of three independent northern blot experiments. 
 
 
3.3 The NF-!B elements in the BIC/miR-155 promoter bind NF-!B 
factors in vitro and in vivo in MC3 cells 
The NF-!B elements in the BIC/miR-155 promoter bind NF-!B factors 
in vitro and in vivo in MC3 cells. To determine the activity of the two 
NF-!B elements identified in the miR-155 promoter, we performed 
EMSA using nuclear extracts from MC3 cells. Briefly, the nuclear 
extracts were incubated with dsDNA oligonucleotides identical to the 
sequence of the NF-!B site 1 (-1150) or 2 (-1697). Both sites 
underwent an electrophoretic mobility shift, which disappeared when 
we used a 80-fold molar cold competitor, but not when we used the 
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same amount of a mutant competitor that is not bound by NF-!B 
complexes (Figure 15A). There was a supershift when  the nuclear 
proteins were pre-incubated with antibodies against p65/RelA or p50, 
two members of the NF-!B family (Figure 15A).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 - The two putative NF-!B binding sites are bound by NF-!B 
complexes in vitro. (A) Electrophoretic mobility shift assay using nuclear extracts 
from MC3 cells (EBV-positive cells) on the two NF-!B binding sites. Left panel: 
NF-!B site 1 (–1150). Right panel: NF-!B site 2 (–1697). WT = 80-fold molar 
cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-
fold molar cold unspecific competitor; p50 = supershift with anti NF-!B p50 
antibody; p65 = supershift with anti NF-!B p65 antibody. Supershift bands are 
indicated with red arrows. 
 
 
Because LMP1 could activate the p52/p65 NF-!B complex (non 
canonical pathway), we repeated the experiment using an anti p52 
antibody, and found no supershift under these conditions. In line with 
the hypothesis that the canonical NF-!B pathway is involved in the 
LMP1-mediated activation of miR-155, we found that miR-155 
expression was inhibited in MC3 cell expressing an exogenous, 
undegradable form of I!B" [142], which is an inhibitor of the canonical 
NF-!B pathway  (figure 16).  
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Figure 16 - Inhibition of NF-!B canonical pathway leads to a reduction of 
miR-155 levels in EBV immortalized MC3 cells.  (A) Western Blot analysis of 
total protein extracts obtained from MC3 untransfected (MC3 UT), MC3 
transfected with pRc/CMV-HA-I!B"-S32/36A (MC3 I!B") and MC3 transfected 
with Empty Vector (MC3 EV). The blot was analyzed for I!B" expression. The 
exogenous protein runs higher than the endgenous because has HA-FLAG. (B) 
Western Blot analysis of nuclear extracts obtained from MC3 untransfected (MC3 
UT), MC3 transfected with pRc/CMV-HA-I!B"-S32/36A (MC3 I!B") and MC3 
transfected with Empty Vector (MC3 EV). The blot was analyzed for p65 
expression and normalized by H3. (C) Graphic representation of the Western blot 
showed in B results as average of three independent experiments. The nuclear p65 
decreases when the undegradable form of I!B" is expressed. (D) Northern Blot 
analysis of total RNAs obtained from MC3 untransfected (MC3 UT), MC3 
transfected with pRc/CMV-HA-I!B"-S32/36A (MC3 I!B") and MC3 transfected 
with Empty Vector (MC3 EV). The blot was analyzed for miR-155 expression and 
normalized by U6. (E) Graphic representation of the Northern blot results as 
average of three independent experiments. 
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To determine whether the NF-!B p50/p65 complex is recruited in vivo 
on the BIC/miR-155 promoter, we examined the two NF-!B sites by 
chromatin immunoprecipitation assay (ChIP). We show that p65 but 
not p50 is engaged on the two NF-!B sites (figure 17A). However, we 
cannot rule out that p50 contributes to the active complex because it 
could simply be covered by DNA and p65, and thus inaccessible to the 
antibody. RNA pol II drives miR-155 transcription [5]. Therefore, we 
checked, in the same experiment if the BIC promoter was also engaged 
by the RNA pol II. As shown in figure 17B we found the RNA 
polymerase on the TATA box of BIC promoter together with p65 
(figure 17A). 
 
Figure 17 - The two putative NF-!B binding sites are bound by NF-!B 
complexes in vivo. (A) ChIP assay of chromatin extracted from MC3 cells using 
polyclonal antibodies directed against the NF-!B p65 or NF-!B p50. After 
immunoprecipitation, the DNA samples were purified and subjected to PCR with 
specific primers amplifying the NF-!B site 1 region (right panel) or NF-!B site 2 
region (left panel). MW = molecular weight marker; p65 = pAB anti NF-!B p65; 
p50 = pAb anti NF-!B p50; "Rab = unspecific polyclonal antibody anti rabbit 
immunoglobulin; IP  input. The red arrows indicate the specific amplified band. (B) 
ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody 
directed against the RNA pol II. After immunoprecipitation, the DNA samples were 
purified and subjected to PCR with specific primers amplifying the TATA box 
region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. 
The two lanes represent two different amounts of input sample used for the PCR; 
"Rab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow 
indicates the specific amplified band. 
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3.4 LMP1 requires intact NF-!B cis-elements to enhance miR-155 
expression  
The foregoing experiments provide compelling evidence that LMP1 
drives miR-155 upregulation and that the miR promoter responds to 
NF-!B transacting factors. However, LMP1 can activate two different 
pathways: the NF-!B pathway and the Jun/Fos (AP-1) pathway [123,125–
127] and the miR-155 promoter has a cis-element responsive to AP-1 40 
nt upstream from the start site [117]. Using truncated forms of BIC 
promoter cloned upstream the luciferase gene reporter, we observed 
that only the first 1380 nt drive the maximum activation of the 
promoter by PMA or LMP1 (figure 18). This could indicate that the 
NF-!B site 2 is irrelevant in the LMP1-mediated activation of miR-
155. To verify the effectiveness of the two NF-!B cis-elements in 
LMP1-enhanced miR-155 promoter, we used both the promoters 
cloned upstream luciferase gene reporter [pLuc1783 wild-type (wt) and 
pLuc1380 wt]. Subsequently, we mutated NF-!B site 1 
(pLuc1783%NF-!B1 and pLuc1380%NF-!B), the AP-1 site 
(pLuc1783%AP-1 and pLuc1380%AP-1) and the NF-!B site 2 
(pLuc1783%NF-!B2) using site-directed mutagenesis. All vectors were 
used for transfection and reporter assay in EBV-negative MEF. As 
shown in figure 18B, pLuc1380 wt was upregulated by about 5-fold 
when cotransfected with a vector expressing LMP1. In the presence of 
LMP1, pLuc1380%NF-!B expression was about 80-fold less, and the 
expression of pLuc1380%AP-1 about 6-fold less than pLuc1380 wt 
expression (figure 18B). These data would suggest that NF-!B site 1 
plays a pivotal role in LMP1 activation and that substantial cooperation 
by the AP-1 site is required to attain maximum activation. Consistent 
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with these results, NF-!B seems to be central also for basal levels of 
miR-155 expression. Indeed, without LMP1, pLuc1380%NF-!B 
expression was about 17-fold lower than pLuc1380 wt expression, 
whereas pLuc1380%AP1 was downregulated by about 3-fold (figure 
18B). When the reporter assays were repeated using the full-length 
vector pLuc1783 wt, induction was reduced (about 3-fold), in the 
presence of LMP1 compared to pLuc1380 wt (compare figure 18B and 
C), which is in line with the results reported in figure 18A. 
Surprisingly, all mutated forms of this vector (pLuc1783%NF-!B2, 
pLuc1783%NF-!B1 and pLuc1783%AP-1) were no longer activated by 
LMP1 expression (figure 18C). The graph in figure 18C is presented in 
logarithmic scale in order to show that the mutations in both NF-!B 
sites dramatically reduced the basal level of miR-155 promoter-driven 
luciferase expression, whereas the AP-1 mutation reduced basal levels 
to a much lesser extent. The latter observation is consistent with our 
data obtained with the truncated promoter. The expression of LMP1 
was checked in each sample (figure 18D) for a further normalization of 
the luciferase assays. These data indicate that both NF-!B cis-elements 
play a central role in LMP1-mediated activation of the promoter and 
may suggest the possible presence of a negative regulatory region 
between the two cis-elements.  
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Figure 18 - NF-!B cis-elements are essential for basal and LMP1-mediated 
activation of miR-155 pomoter. (A) Luciferase assay performed in De Few cells 
using the full-length miR-155 promoter and two truncated forms. The transfected 
cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the 
truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase 
activity. The graphic representation of the luciferase assay is the average of three 
independent experiments. (B and C) The indicated miR-155 promoter luciferase 
vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated 
for 48 h in MEF cells. Luciferase expression was normalized by !-gal/µg of total 
protein and represented as average of three independent experiments. (D) Western 
blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by #-
tubulin. 
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3.5 The binding of p65/RelA to both NF-!B cis-elements of miR-
155 promoter is temporally correlated to LMP1 expression 
To determine whether the exogenous expression of LMP1, in DeFew 
cells, is correlated temporally with the upregulation of the endogenous 
miR-155, we performed a time-course experiment in DeFew cells 
infected with pBABEpuroLMP1 or with the empty vector as control. 
Each time point was split into three for western blot, northern blot and 
ChIP analyses. LMP1 expression was observed 24 h post-infection and 
peaked at 72 h (figure 19A and B), whereas the upregulation of miR-
155 occurred at 48 h post-infection and increased at 72 h (figure 19C 
and D). These results indicate that the upregulation of miR-155 is 
temporally dependent on the expression of LMP1 (figure 19E).  
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To further clarify the function of the two NF-!B cis-elements in the 
endogenous miR-155 promoter, we performed ChIP analysis followed 
by semi-quantitative PCR. There was constitutive binding of p65/RelA 
on both NF-!B sites (figure 20A, left panel and figure 20B). This 
binding did not increase in the cells infected with the empty vector 
(figure 20A, left panel). In contrast, in the cells expressing LMP1, the 
binding of p65/RelA on NF-!B 1 site increased 1.5-fold at 24 h and 
3.5-fold at 72 h (figure 20A, left panel and figure 20B), whereas the 
binding of p65/RelA on the NF-!B 2 site increased 1.3-fold at 24 h and 
2.5-fold at 72 h (figure 20A, left panel and figure 20B). At the same 
time points, the binding of RNA pol II on the TATA box of BIC 
promoter increased in the LMP1-infected cells but not in the control 
cells control and the assay was normalized against histone H3 (figure 
20A and C, right panel). Taken together, these data and the results 
reported in figure 20 strongly suggest that LMP1 activates p65 binding 
on miR-155 promoter and this lead to upregulation of miR expression. 
 
Figure 19 - Time-course of LMP1-mediated activation of miR-155. (A) Western 
blot analysis of protein extracts obtained at indicated times from DeFew cells 
infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the 
expression of LMP1 and normalized by #-tub. (B) Graphic representation of the 
western blot results. (C) Northern blot analysis of RNAs obtained at indicated times 
from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. 
The blot was analyzed for the expression of miR-155 and normalized by U6. (D) 
Graphic representation of the northern blot results. (E) Graphic representation of 
the correlation of miR-155 and LMP1 expression at indicated times. 
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Figure 20 - Semi-quantitative ChIP on the BIC promoter at indicated times in 
DeFew cells after retroviral infection with a vector expressing LMP1 or empty 
vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells 
infected with pBABEpuroLMP1 or empty vector. (A) left panel: After 
immunoprecipitation with the indicated antibodies, the DNA samples were purified 
and subjected to PCR with specific primers amplifying the NF-!B site 1 region or 
NF-!B site 2 region. MW = molecular weight marker; p65 = pAB anti NF-!B p65; 
ti NF-!B; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the 
DNA samples were purified and subjected to PCR with specific primers amplifying 
the G3PDH promoter region. (B) Graphic of the results showed in panel (A; C) 
After immunoprecipitation with mAb directed against the RNA pol II, the DNA 
samples were purified and subjected to PCR with specific primers amplifying the 
TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; 
H3 = pAb anti Histone H3. 
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3.6 The protein levels of transcription factor PU.1 correlates with 
LMP1-induced miR-155 expression  
It was recently reported that miR-155 targets PU.1 mRNA thereby 
affecting its translation [110]. Hence, we checked whether the levels of 
protein PU.1 could be lowered by LMP1 activation of miR-155. To this 
aim, we infected DeFew cells with the retroviral vector expressing  
LMP1 or with the empty vector as control. The results show a 2-fold 
decrease of PU.1 protein levels in the DeFew cells infected with LMP1-
expressing vector versus empty vector (figure 21A and B). In the same 
experiment, we ran a northern blot analysis to evaluate miR-155 
expression. As shown in figure 21C and D, miR-155 expression in 
LMP1-expressing DeFew cells was 10-fold higher than in the empty 
vector. Interestingly, PU-1 levels were very low in EBV-immortalized 
MC3 cells overexpressing miR-155. 
         
 
 
 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
64 
3.7 Discussion 
 
microRNAs, like transcription factors, regulate the expression of 
several genes post-transcriptionally, and are thus important players in 
such relevant cellular processes as cell growth, differentiation, cell 
signaling and apoptosis. miRNAs themselves are subjected to fine 
expression regulation, their transcription being driven by RNA pol II 
responsive promoters [5]. It is generally recognized that miRNAs play a 
central role in the molecular etiology and maintenance of cancer. 
In this study, we describe the activation of miR-155, which is a 
potential oncomiR [143], by LMP1, a trans-membrane EBV protein 
considered to be the major oncoprotein of EBV. LMP1 is expressed 
during viral latency and it activates the signaling pathways NF-!B and 
AP-1 [129]. Using miRNA array, it has been reported that LMP1-induced 
the expression of numerous miRNAs, such as miR-146, whose 
expression is upregulated by the LMP1-induced NF-!B pathway [145,146]. 
Here we show that EBV-infected cells constitutively express high 
levels of miR-155, and that the exogenous expression of LMP1 in 
EBV-negative B cells enhances miR-155 expression in a time- and 
dose-dependent manner (figure 20).  
 
Figure 21 - PU.1 protein levels correlate with LMP1-mediated activation of 
miR-155 expression. (A) western blot analysis of PU.1 expression in EBV-
immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with 
pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of 
puromycin for 7 days (DeFew Empty Vector); (B) Graph of densitometric analysis 
of A normalized by #-tubulin; (C) northern blot analysis of mir-155 expression in 
EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with 
pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and 
selected with 1 mg/ml of puromycin for 7 days; (D) Graph of densitometric 
analysis of C normalized by U6. 
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Yin et al. [117] reported that the promoter of the BIC gene encoding miR-
155 contains a conserved AP-1 element 40 bases upstream from the 
transcription start site that is essential for the induction of miR-155 
mediated by activation of the BCR [117]. They also identified a putative 
NF-!B site at –1150 nt on the BIC promoter whose mutation did not 
affect miRNA enhancement by activation of the BCR [117]. We found an 
additional NF-!B putative binding site at –1697 nt on the BIC 
promoter. We show that the endogenous promoter is responsive to 
PMA (figure 14), a well recognized activator of the canonical inhibitor 
kinase kinase-dependent (IKK) [141] NF-!B pathway. Moreover, both 
putative NF-!B sites were able to bind in vitro the NF-!B proteins p50 
and p65 in nuclear extract from MC3 cells (figure 15A). 
Because LMP1 induces both the canonical IKK-dependent [147] and 
non-canonical NF-!B-induced kinase-dependent (NIK) [148] NF-!B 
pathways, we tested whether p52 (an NF-!B protein activated by a non-
canonical pathway) was part of the binding complex, but we did not 
detect it. Accordingly, inhibition of the canonical NF-!B pathway by 
exogenous expression of I!B" led to reduced expression of miR-155 in 
MC3 (figure 16). This could indicate that the non-canonical pathway is 
activated only at the beginning of EBV infection when the virus needs 
to maximize this signaling pathway. 
Furthermore, both the NF-!B sites bound to p65 in vivo as did the RNA 
pol II on the TATA box of the BIC promoter, in MC3, which indicates 
ongoing miR-155 transcription (figure 17A and B) suggesting that the 
two NF-!B sites are active in an EBV-positive background. However, 
PMA- and LMP1-driven induction was higher with a truncated form of 
the BIC promoter lacking the distal site (NF-!B site 2) than with the 
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full-length promoter (figures 18A). To shield light on the effectiveness 
of the two NF-!B cis-elements, we performed reporter assays using the 
full length (pLuc1783) or a truncated form (pLuc1380) of miR-155 
promoters either wild-type or mutated in the NF-!B site 1, NF-!B site 
2 or AP-1. Our results indicate that both NF-!B sites are pivotal for 
basal and LMP1-induced expression of miR-155 (figure 18B and C). 
Conversely, mutation of the AP-1 site in the pLuc1380 reduced the 
constitutive expression of the promoter, which in fact was still 
inducible by LMP1 albeit to a lesser extent (figure 18B). However, 
mutation of the AP-1 site in the pLuc 1783 abolished the LMP1-
induced expression. Yin et al. [149] suggested that miR-155 promoter 
contains one or more CpG islands. The presence of putative CpG as 
well as cis-elements bound by negative regulatory protein(s) or 
promoter secondary structures could explain why the truncated form of 
the promoter, lacking this putative NRE, is inducible at higher extent 
by both PMA and LMP1. 
Subsequently, we performed time-course experiments in EBV-negative 
cells infected with an exogenous LMP1. Our data show that the 
expression of LMP1 is temporally correlated with the activation of p65 
binding on both NF-!B sites (figure 20), recruitment of RNA pol II and 
miR-155 induction (figures 19 and 20). All data reported give a clear 
indication that LMP1 enhances miR-155 expression, mainly, via 
activation of the canonical NF-!B pathway. 
Our results, together with the previous data reported by Yin et al. [117], 
illustrate the exquisite regulation of this miR by various stimuli, and 
highlight its importance in B-cell physiology. 
microRNAs in the control of lymphocytes response 
 
 
  
 
 
67 
PU.1 is a downstream effector of miR-155 thanks to the presence of a 
miR-155 complementary seed sequence in the 3' UTR of PU.1 mRNA 
[110]. In the latter report, B cells lacking miR-155 generated reduced 
extrafollicular and germinal center responses and did not produce high-
affinity IgG1 antibodies. PU.1 is highly expressed in miR-155-deficient 
B cells and its overexpression in wild-type B cells results in reduced 
numbers of IgG1-switched cells, which indicates that miR-155 plays a 
key role in antigen-driven B-cell maturation. PU.1 is a master gene of 
the Ets transcriptional factor family that promotes cell growth, 
differentiation and apoptosis thereby playing an important role in 
hematopoiesis [112]. It is both an oncogene [112] and a tumor suppressor 
gene that promotes apoptosis. Here we show that LMP1-mediated 
activation of miR-155 is correlated with diminished levels of the PU.1 
protein (figure 21). Many mRNAs were predicted to be direct targets of 
miR-155. A recent work reported that miR-155 plays an important role 
in EBV-regulated gene expression of the infected cells [117]. It is thus 
possible that the phenotypic alterations and the oncogenic potentialities 
observed in miR-155-overexpressing mice[143] are the result of 
deregulation of other targets in addition to PU.1. In silico analysis 
indicated that miR-155 may target SOCS1[150] and WEE1[151] (Mallardo 
et al. unpublished data), which would better account for its oncogenic 
role. Probably, a miRNA can have two or more targets or even different 
targets depending on the cellular context. Studies to elucidate the 
molecular targets of miR-155 after LMP1 induction, and to determine 
their reciprocal role during EBV infection and EBV-mediated 
transformation are underway in our laboratory. 
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Chapter 4: Computational analysis and in vivo validation 
of a microRNA encoded by the IBTK gene, a regulator of 
B-lymphocytes differentiation and survival 
 
4.1 IBTK gene encoded a new microRNA 
 
To identify putative pre-miRs encoded by the IBTK gene, we 
performed the in silico analysis of the genomic nucleotide sequence of 
the IBTK genetic locus by using the Pro-MirII software that allows the 
probabilistic prediction of clustered, un-clustered, conserved and un-
conserved [152]. We identified four potential miRNAs located in the 
introns 17, 21, 26 and in the 3’ UTR of the IBTK gene, named pre-
miR-IBTK1, pre-miR-IBTK2, pre-miR-IBTK3, pre-miR-IBTK4, 
respectively, according to chemical and physical properties, such as 
free energy, G-C ratio and entropy (figure 22).  
        
Figure 22 - Precursor bioinformatic analysis of the genetic locus IBTK. (A) 
Chemical-physical properties (free energy, G-C ratio, entropy) of the four predicted 
microRNA precursors encoded by the human genetic locus IBTK on the 
chromosome 6. (B) Bidimensional representation  of the predicted microRNA 
precursors by using PromirII software. 
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To assess whether the predicted pre-miRs were substrates of RNase III 
Dicer, we generated expression vectors of pre-miR-IBTK sequences 
under the T7 promoter, which were used to produce the relative [32P]$-
UTP-labeled transcripts. By in vitro assay, pre-miR-IBTK3, and not the 
other pre-miRs, was cleaved by the human recombinant Dicer to 
generate 22-25 nucleotides RNA products (figure 23). 
 
Figure 23 - In vitro Dicer RNase assay. In vitro transcribed and labeled  pre-miR-
IBTK1(lane 2,3), pre-miR-IBTK2 (lane 4,5), pre-miR-IBTK3 (lane 6,7), pre-miR-
IBTK4 (lane 8,9),were incubated for two hours in the presence (3,5,7,9) or 
absences (2,4,6,8) of recombinant Dicer. Products were resolved on a 15% TBE-
Urea gel and visualized by autoradiography. Arrow indicates the ~22 nt band 
generated by Dicer cleavage. MW (lane1) was exposed for 1 minutes, while the 
digests (lanes 3,5,7,9) were exposed for 15 minutes. Numbers to the left indicate 
the size of the associated RNA marker. 
 
 
 
Then, we performed the Northern blotting analysis of total RNA 
extracted from human PBMCs to verify the in vivo occurrence of pre-
miR-IBTK3 and relative products under physiological conditions. To 
this end, we used 25 nucleotides-probes annealing to four sequential 
regions of pre-miR-IBTK3 (figure 24A). All nucleotide probes 
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identified both the pre-miR-IBTK3 and IBTK miRNA (figure 24B), 
indicating that both arms of pre-miR-IBTK3 generated the RNA 
products in vivo. 
            
 
Figure 24 - Northern blot analysis of microRNAs encoded by genetic locus 
IBTK. (A) Schematic representation of the probes used in northern blotting 
analysis. (B) Northern blotting of total RNA extracted from PBMC. 
 
 
To evaluate the grade of evolutionary conservation of pre-miR-IBTK3, 
we performed a CLUSTALW-based multiple sequence alignment of 
the nucleotide sequence of pre-miR-IBTK3 in different vertebrates. The 
pre-miR-IBTK3 of Homo sapiens showed a high identity degree with 
pre-miR-IBTK3 of Pan troglodytes, Pongo pygmaeus and Macaca 
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mulatta, and a lower identity degree with pre-miR-IBTK3 of Bos 
Taurus and Canis Familiaris (figure 25).  
 
Figure 25 - Comparative analyses of pre-miR-IBTK3 among different species. 
Alignement of the  nucleotide sequence of Homo sapiens pre-mir-IBTK3 with the 
homologs nucleotide sequences of Pan troglodytes, Pongo pygmaeus, Macaca 
mulatta, Bos Taurus and Canis Familiaris. The identity percentage among these 
sequences was calculated by using CLUSTALW software. 
 
 
 
In fact, the identity percentage of Homo sapiens pre-miR-IBTK3 as 
compared to the pre-miR-IBTK3 of Pan troglodytes, Pongo pygmaeus 
and Macaca mulatta was 95%, 90.4% and 87.5%, respectively. 
Differently, the identity percentage compared with the pre-miR-IBTK3 
of Bos taurus and Canis familiaris was 70% and 69%, respectively. 
Accordingly, the PromirII-based analysis of pre-miR IBTK3 nucleotide 
sequence of Pan troglodytes, Pongo pygmaeus and Macaca mulatta 
predicted a miRNA secondary structure (figure 26), which was not 
predicted for the homologue IBTK nucleotide sequence of Bos taurus 
and Canis familiaris. 
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Figure 26 - Precursor bioinformatic analysis of the homologs pre-mir-IBTK3 
sequences in Pan troglodytes, Pongo pygmaeus, Macaca mulatta. (A) The table 
shows the Chemical-physical properties (free energy, G-C ratio, entropy) of the 
predicted pre-mirIBTK3 in different species. (B) Bi-dimensional representation  of 
the predicted  pre-miRIBTK3 in primates Pan troglodytes, Pongo pygmaeus and 
Macaca mulatta. 
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4.2 Discussion 
 
The IBTK genetic locus encodes the IBtk proteins ", $, # [131]. We 
previously characterized IBtk#  as a repressor of Btk [131,132]. Btk is a 
Tec tyrosine kinase required for B-lymphocytes development and 
differentiation [153]. Mutations of the BTK gene inactivating the Btk 
activity caused X-linked agammaglobulinemia in humans [154] and X-
linked immunodeficiency in mice [155]. In mature B-lymphocytes, Btk is 
required for calcium signalling and activation of the anti-apoptotic 
transacting factor NF-!B in response to the triggering of the B cell 
receptor for the antigen (Janda E. et. al., submitted); in this context, Btk 
promotes the antibody production, B cell differentiation and cell cycle 
progression. IBtk# binds the pleckstrin homology (PH) domain of Btk 
and represses the Btk-mediated signalling leading to B-cell activation 
[131,132]. Based on this evidence, IBTK exerts a prevalent anti-
proliferative action. Moreover, IBTK might play a more extended role 
in cell signalling since the IBtk" and IBtk#  proteins are expressed in 
distinct cell types and bind the PH domain o distinct Tec kinases, such 
as Btk, Itk and Akt [131]. Two promoters and several cis regulatory 
sequences were identified in the IBTK gene [131]; however, little is 
known on the IBTK transcription regulation. Recent studies have shown 
that miRNAs regulate cell proliferation and apoptosis and are involved 
in cancer development [156]. Indeed, more than 50% of miRNA genes 
are located either in cancer-associated genomic region, or in fragile 
sites, suggesting that miRNAs rearrangements may play a major role in 
the pathogenesis of human cancers [157, 158]. In particular, B and T cell 
neoplasia showed a high incidence of miRNAs rearrangements [159, 160], 
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indicating that specific miRNAs mutations may deregulate cell 
functions that play a role in B and T lymphocyte proliferation. 
In this study, we have addressed whether the IBTK gene generates 
miRNAs in human PBMCs. We found that intron 26 of the human 
IBTK gene encodes the premiR IBTK3, which is cleaved by Dicer 
generating ~22-nucleotide-long products. This finding correlated with 
the occurrence of pre-miR IBTK3 and the relative miRNA products in 
human PBMCs. We also found that pre-miR IBTK3 is an evolutionary 
conserved function in primates since it is highly conserved in Pan 
troglodytes, Pongo pygmaeus and Macaca mulatta. The evidence of 
miRNA IBTK occurrence in vivo supports an expanded role of the 
IBTK gene as regulator of gene transcription through miRNA 
generation. As the human IBTK gene is located in the genomic 
sequence 6q14.1, which is a region of recurrent chromosomal 
aberration in lymphoproliferative disorders [1363, our findings suggest 
that aberrant production of IBTK miRNA might be involved in 
tumorigenesis. Identification of the primary structure of the IBtk 
miRNA in vivo will be required to identify its mRNA targets and 
specific function in gene regulation. 
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